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CARDIOVASCULAR disease (CVD) is a major causeof morbidity and mortality after renal transplantation
(RT).1,2 The excess risk of CVD in RT is due in part to a
higher prevalence of established atherosclerotic risk factors,
including hypertension, dyslipidemia, diabetes, obesity, and
physical inactivity.1,2 However, some renal-related risk fac-
tors like immunosuppressive medication and residual renal
insufficiency also contribute to this excess CVD risk and
may complicate the management of dyslipidemia and hy-
pertension in this population.1,2 Accordingly, there is a
compelling need to identify and safely manage other puta-
tive CVD risk factors among RT patients. Elevated plasma
homocysteine is emerging as an important risk factor for
cardiovascular disease in general populations.3,4 Some stud-
ies have demonstrated that hyperhomocysteinemia is
present in patients with impaired renal function and is
associated with CVD.5–7 Only a small number of studies are
available on the prevalence and determinants of hyperho-
mocysteinemia in renal transplant recipients.8–15 We un-
dertook this study to
1. estimate the prevalence of hyperhomocysteinemia in
renal transplant recipients;
2. examine the relationships between plasma total homo-
cysteine (tHcy) and its metabolic determinants vita-
min B6, vitamin B12, and folic acid; and
3. identify other determinants of tHcy.
MATERIALS AND METHODS
A cross-sectional study was conducted in 202 stable RT recipients
(113 male, 89 female), selected from 633 RT patients with func-
tioning allografts of our Renal Transplant Unit. All recipients
received grafts from cadaver donors. The eligibility criteria were:
age over 18 years, first renal allograft, time since RT of at least 6
months, and stable plasma creatinine values during 3 months prior
to study. Patients with diagnosis of any kind of cancer, clinical or
analytical evidence of liver disease, and chronic alcoholism were
also excluded. None of the selected RT recipients were taking B
vitamin.
The mean age was 44 6 11 years (range, 21 to 71; median, 43).
The mean duration after renal transplantation was 58.5 6 37.2
months (range, 17 to 192; median, 50.6). Patients had been on
dialysis for an average of 42.7 6 37.5 months (range, 0 to 221;
median, 30.5) before transplantation. Mean serum creatinine value
was 1.5 6 0.6 mg/dL (range, 0.6 to 4.7; median, 1.4) at the time
blood was drawn for this study. Immunosuppression protocol of the
202 RT patients is described on Table 1.
The Ethics Committee of Santo Antonio Hospital approved the
study protocol, and all participants provided written informed
consent.
Biochemical Determinations
Overnight fasting blood samples were collected from each partic-
ipant. Total fasting homocysteine levels were determined by polar-
ized immunofluorescence on an automated Abbott IMx analyzer.
Hyperhomocysteinemia was considered if plasma levels of fasting
tHcy were higher than 15 mmol/L. Plasma pyridoxal 59-phosphate
was determined by high performance liquid chromatography with
fluorescence detection. Plasma vitamin B12, plasma, and erythro-
cyte folate were measured on automated analyzer ACS: Centaur
(Chiron Diagnostics) by chemioluminescence. Laboratory tests
performed included serum measurements of creatinine, urea, uric
acid, albumin, total protein, HDL, LDL, total cholesterol, and
apolipoproteins A and B-100.
Statistical Analysis
Logarithmic transformations and geometric means were used for
continuous variables with a positively skewed distribution. Means
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Table 1. Immunosuppression Protocol
Immunosuppression Protocol
Total
(n 5 202)
(%)
Male
(n 5 113)
(44.1%)
Female
(n 5 89)
(55.9%)
Prednisolone 1 azathioprine 1 (0.5) — 1 (0.5)
Prednisolone 1 cyclosporine 86 (42.6) 53 (46.9) 33 (37.1)
Prednisolone 1 cyclosporine
1 azathioprine
71 (35.1) 39 (34.5) 32 (36.0)
Prednisolone 1 cyclosporine
1 MMF
25 (12.4) 14 (12.4) 11 (12.4)
Prednisolone 1 tacrolimus 3 (1.5) 1 (0.9) 2 (2.2)
Prednisolone 1 tacrolimus 1
MMF
1 (0.5) — 1 (1.1)
Cyclosporine 4 (2.0) 1 (0.9) 3 (3.4)
Cyclosporine 1 azathioprine 10 (5.0) 5 (4.4) 5 (5.6)
Cyclosporine 1 MMF* 1 (0.5) — 1 (1.1)
*MMF: mycophenolate mofetil.
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of continuous variables were compared by Student’s t test. Differ-
ences in proportions between groups were studied using the x2.
Correlation between continuous variables was assessed by Pearson
correlation.
RESULTS
The prevalence of fasting hyperhomocysteinemia was
48.7%, and it was significantly higher in male patients than
in female (31.9% vs 16.8%; P , .05). Geometric mean of
tHcy was 14.9 mmol/L and tHcy levels were significantly
higher in male RT patients than in females (16.2 vs 13.4
mmol/L; P , .001).
Significant correlations were found between tHcy and
plasma creatinine (r 5 .55; P , .001), urea (r 5 .49; P ,
.001), and uric acid (r 5 .51; P , .001).
No significant vitamin deficiencies were found in our
patients. None of them had plasma folate concentrations
under the lower limit of normal reference range. Plasma
concentrations of vitamins B6 and B12 were low only in
three patients (2.2 and 1.5%, respectively) and erythrocyte
folate was below lower limit in only 12 patients (6.6%)
(Table 2). Nevertheless, we found a negative statistically
significant correlation between tHcy and plasma folate (r 5
.36; P , .001), erythrocyte folate (r 5 .25; P 5 .001), and
vitamin B12 (r 5 .27; P , .001). There was no significant
relationship between fasting tHcy and vitamin B6.
No significant linear correlation was found between tHcy
and age, body mass index, serum albumin, total protein,
triglycerides, total and LDL cholesterol, lipoprotein (a),
and apolipoprotein B-100. In addition, there was no signif-
icant correlation between tHcy and dose or plasma levels of
cyclosporine (P . .05).
DISCUSSION
Renal transplantation is a recognized treatment for end-
stage renal failure. CVD represents a major cause of both
morbidity and mortality.1,2 Recent reports summarizing
large collaborative studies show that increased tHcy is an
important and independent risk factor for morbidity and
mortality of CVD disease.3,4 Several reports in RT also
point out that hyperhomocysteinemia is present in RT
patients,9,10–15 but limited data are available on the preva-
lence of hyperhomocysteinemia in stable RT recipi-
ents.9,12,14,15 We have confirmed the presence of increased
levels of tHcy, showing that 48.7% of our stable RT patients
had hyperhomocysteinemia, mainly in males.
We have found that tHcy is correlated both with concen-
trations of creatinine and of urea, indicating that the degree
of renal impairment is a major influence on homocysteine
levels. This finding agrees with other studies.8,12–15
In our study, even within their normal range, tHcy were
negative and significantly correlated with folic acid and
vitamin B12 concentrations. However, it is unlikely that
elevated levels of tHcy are attributable to deficiencies of
these vitamins, because RT patients can have a regular diet
without the restrictions that characterize dialysis patients.
We confirmed this finding: no significant deficiencies were
found in our patients. More than 90% had normal or higher
levels of those vitamins.
Like other studies in RT population,9,12,14 a significant
correlation between tHcy and age was not found. Also, a
significant relationship was not found between tHcy and
other risk factors for atherosclerosis like plasmatic lipids
and body mass index. This analysis was not performed in
any of the studies conducted in RT patients.
Arnadottir et al suggests the possibility that cyclosporine
use is associated with increased tHcy levels among RT
recipients.9 But, as in other studies, we didn’t find any
correlation between tHcy levels and dose and plasma levels
of cyclosporine.10–15
CONCLUSIONS
In this study we found that hyperhomocysteinemia is com-
mon in RT patients and occurs despite normal concentra-
tions of folate and vitamins B12 and B6. As in general
population, folic acid and B12 were significant determinants
of fasting tHcy. Serum creatinine, urea, and uric acid were
also important determinants of tHcy. Plasma lipids and
cyclosporine appear not to influence tHcy.
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